This review seeks to shed light on a relatively common but poorly understood adverse effect of radiotherapy for primary and metastatic brain or head and neck tumors.
Despite improved survival in patients with B cell malignancies who are treated with PI3K inhibitors, researchers found incidences of pneumonitis, infections, and sepsis are higher in these patients.
New scoring method provides a more nuanced risk stratification of VTE than the Khorana score in ambulatory patients with cancer.
Data from an ongoing trial of luspatercept, an erythroid maturation agent, in patients with myelofibrosis and anemia shows promise of clinically significant activity with low level of grade 3/4 adverse effects.
A prospective study followed more than 3000 patients with lymphoma to determine the potential risk for developing anthracycline-induced CVD.
Researchers sought to determine if corticosteroids can be used to effectively manage CRS in patients undergoing CAR-T therapy without negatively influencing outcomes.
In a safety expansion of the ZUMA-1 study, researchers found that steroids may reduce incidence of CRS and neurologic events associated with CAR-T therapy in patients with relapsed/refractory large B cell lymphoma.
Risk highest in the year after diagnosis but remains elevated compared with general population.
Diagnosis and management of EF in the setting of cancer immunotherapy requires close collaboration between patient’s oncologist, dermatologist, and rheumatologist.
The TEAMM trial sought to assess time to first febrile episode or death from all causes in patients with newly diagnosed myeloma who received antibiotic prophylaxis vs those who did not.